Beyond hairy cell: the activity of cladribine in other hematologic malignancies

Blood
Darren S SigalAlan Saven

Abstract

Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent. Its profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and a median duration of response of nearly a decade after only a single 7-day course, is well known and revolutionized the treatment of hairy cell leukemia. However, cladribine's impressive activity in other lymphoproliferative disorders has been generally underappreciated. Multiple single-arm phase 2 trials have demonstrated cladribine's potency across the full spectrum of lymphoid malignancies. In a limited number of phase 3 trials and cross-study analyses, cladribine compared favorably with fludarabine, another purine nucleoside analog that is more commonly used in the treatment of indolent lymphoid malignancies. Cladribine has been noted to have particular activity among lymphoid disorders with few effective therapies, specifically, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Recently approved novel agents may act in synergy with cladribine for these conditions and should be incorporated into future clinical studies.

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonJ E Seegmiller
Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·A CohenD W Martin
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C KayL D Piro
Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J LiliemarkG Juliusson
Oct 17, 1992·Lancet·E Beutler
Feb 1, 1985·The Journal of Clinical Investigation·S SetoD A Carson
Jun 1, 1986·Experimental Cell Research·D A CarsonC J Carrera
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonJ A Montgomery
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonE Beutler
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S TallmanD Variakojis
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HoffmanK Rai
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonJ M Sorensen
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosR Alexanian
Feb 1, 1993·Annals of Internal Medicine·M A DimopoulosR Alexanian
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A TefferiM M Ames
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL Piro
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Juliusson, J Liliemark
Oct 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D C BetticherT Cerny
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL Piro
Jan 1, 1997·Leukemia & Lymphoma·V A CanfieldC Nichols
May 7, 1998·Leukemia & Lymphoma·G NadaliG Pizzolo
Jun 9, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T RobakI Urasiński
Jul 31, 1998·Leukemia & Lymphoma·R C ChastyJ A Copplestone
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·L M LeoniD A Carson
Aug 26, 1998·Leukemia & Lymphoma·J LiliemarkG Juliusson
Dec 19, 1998·British Journal of Haematology·E S LiuA Saven
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A FridrikW Linkesch
Mar 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J RummelP S Mitrou

❮ Previous
Next ❯

Citations

Jul 2, 2011·Case Reports in Neurology·E BroussalisM Killer-Oberpfalzer
Jun 1, 2011·Leukemia & Lymphoma·Stephen E SpurgeonElliot M Epner
Apr 21, 2011·Leukemia & Lymphoma·Melissa L TorreyAlan Saven
Jan 8, 2013·Leukemia & Lymphoma·Jeremy S AbramsonEphraim P Hochberg
Oct 17, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sakilam SatishkumarMahesh K Lakshman
Dec 22, 2012·Expert Opinion on Pharmacotherapy·Giancarlo ComiMatthew Scaramozza
Jul 8, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Clemens WarnkeHans-Peter Hartung
Aug 19, 2011·American Journal of Clinical Pathology·Michael J ShermanJames D Hoyer
Dec 15, 2017·Frontiers in Medicine·Vibeke Andresen, Bjørn T Gjertsen
Jun 15, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Kenichiro KudoKatsuyuki Kiura
Oct 3, 2019·Scientific Reports·Anastazja PocztaAgnieszka Marczak
Oct 9, 2019·Biotechnology Progress·María J LapponiJorge A Trelles
Nov 23, 2019·Leukemia & Lymphoma·Matteo MolicaTapan Mahendra Kadia
Jun 10, 2017·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Ankur JainSubhash Varma
Aug 28, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A N BoykoO G Kulakova
Jan 31, 2018·Proceedings of the National Academy of Sciences of the United States of America·Therese TriemerNathan W Luedtke
Nov 25, 2018·Annals of Hematology·Ayman QasrawiRakesh Gaur
Jun 23, 2015·Expert Review of Neurotherapeutics·Emanuele D'AmicoFrancesco Patti
Nov 27, 2020·International Journal of General Medicine·Huijie DongDijiong Wu
Nov 12, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sakilam SatishkumarMahesh K Lakshman
Apr 15, 2021·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Federico CarliniAntonio Uccelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.